1,356,397 Illumina, Inc. $ILMN Shares Bought by Ninety One UK Ltd

Ninety One UK Ltd lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 37,920.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,359,974 shares of the life sciences company’s stock after acquiring an additional 1,356,397 shares during the quarter. Ninety One UK Ltd’s holdings in Illumina were worth $372,198,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in Illumina in the second quarter valued at about $3,374,423,000. Primecap Management Co. CA acquired a new stake in shares of Illumina during the second quarter valued at about $617,981,000. Jupiter Topco LLC acquired a new stake in shares of Illumina during the second quarter valued at about $358,652,000. WCM Investment Management LLC boosted its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Illumina during the second quarter worth about $293,846,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. Guggenheim boosted their price target on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Sunday. Royal Bank Of Canada boosted their target price on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Finally, TD Cowen upped their price target on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $225.94.

Illumina Trading Down 0.6%

NASDAQ:ILMN traded down $1.60 during trading hours on Thursday, hitting $270.16. 1,379,613 shares of the company were exchanged, compared to its average volume of 2,167,091. The stock has a market capitalization of $40.79 billion, a price-to-earnings ratio of 50.23, a price-to-earnings-growth ratio of 3.84 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a one year low of $93.50 and a one year high of $309.35. The company has a fifty day simple moving average of $231.55 and a 200 day simple moving average of $184.42.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $1.19 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity

In other news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,061,850 shares of company stock worth $436,479,102 in the last ninety days. 2.90% of the stock is owned by company insiders.

Illumina Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.